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Southern Italy, Journal of MicrobioloBackground: Bartonella henselae is the etiologic agent of cat-scratch disease. B. henselae in-
fections are responsible for a widening spectrum of human diseases, although often symptom-
less, ranging from self-limited to life-threatening and show different courses and organ
involvement due to the balance between host and pathogen. The role of the host immune
response to B. henselae is critical in preventing progression to systemic disease. Indeed in
immunocompromised patients, such as solid organ transplant patients, B. henselae results in
severe disseminated disease and pathologic vasoproliferation. The purpose of this study was
to determine the seroprevalence of B. henselae in patients awaiting heart transplant
compared to healthy individuals enrolled in the Regional Reference Laboratory of Transplant
Immunology of Second University of Naples.
Methods: Serum samples of 38 patients awaiting heart transplant in comparison to 50 healthy
donors were examined using immunfluorescence assay.
Results: We found a B. henselae significant antibody positivity rate of 21% in patients awaiting
heart transplant (pZ 0.002). There was a positive rate of 8% (p > 0.05) for immunoglobulin (Ig)
M and a significant value of 13% (pZ 0.02) for IgG, whereas controls were negative both for IgM
and IgG antibodies against B. henselae. The differences in comorbidity between cases and con-
trols were statistically different (1.41  0.96 vs 0.42  0.32; p Z 0.001).
Conclusions: Although this study was conducted in a small number of patients, we suggest that
the identification of these bacteria should be included as a routine screening analysis in pre-
transplant patients.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Bartonella spp. are intracellular Gram-negative bacteria.
Bartonella henselae has the ability to invade human
erythrocytes1e3 and other cells, such as hematopoietic
stem cells (HSCs) proposed as putative niches of Bartonella
spp.4 It is known that B. henselae is able to adhere to and
also invade endothelial progenitor cells (EPCs).5 During B.
henselae infection, the invasion of bacteria subverts many
functions of human host cells6; indeed, it directly induces
endothelial proliferation by inhibiting the host cell
apoptosis, thus allowing its permanence into the cell host
habitat.7,8
The pathological response to B. henselae infection de-
pends on the host immune status.9 The immune response has
a reduced ability to control the infection resulting in a longer
duration of bacteremia.10 These bacteria are rapidly
becoming prominent as emerging pathogens causing both
acute or chronic infections and vascular proliferative or
suppurative manifestations.11 B. henselae infections may
cause a variety of human diseases, often symptomless, that
show different evolution and organ involvement due to the
balance between host and pathogenic factors.12 Indeed, in
immunocompetents, these bacteria often cause self-limiting
infections usually with fever and regional lymphadenopathy,
known as cat-scratch disease, which can resolve spontane-
ously without treatment.13 However, in immunocomprom-
ized patients B. henselae results in severe disseminated
diseases and pathologic vasoproliferation known as bacillary
angiomatosis and bacillary peliosis that most commonly
involve skin or lymphonodes and liver or spleen, respec-
tively.11 In addition, B. henselae infection can result in
endocarditis due to endovascular bacteria replication.14
Because their evolutionary ability is to induce persistentPicascia A, et al., Seroprevalence
gy, Immunology and Infection (20intravascular infections, B. henselae is an unexpectedly
major cause of blood culture-negative endocarditis, espe-
cially in patients with preexisting valve heart disease.15,16
Epidemiological human studies have increased in the
past decade with a high degree of variation of antibody
prevalence of B. henselae in the world.12,17 However, B.
henselae has been reported in several geographic areas of
Europe.18,19 In Italy, B. henselae infection is probably
underdiagnosed due to the high frequency of atypical onset
of clinical manifestations as reported by several stud-
ies.20e23 The seropositivity of B. henselae in the stray cat
populations in Northern Italy is approximately 40%, and
12.2% shows both bacteremia detection and seroposi-
tivity.24 Until now, there are no data on Bartonella preva-
lence in our region, in either human or cat populations.25
The direct identification of Bartonella is difficult due to
its slow growing characteristic and, therefore, is usually
delayed.15 Unlike molecular and histological methods that
require a tissue sample, serological assays utilize only a
small blood sample for a reliable diagnosis.26 Therefore,
diagnosis of B. henselae is mainly based on serological
methods [immunoglobulin (Ig)M, IgG detection] for their
ease and speed.
Diagnosis and management of B. henselae infection in
solid organ transplant recipients has not been well char-
acterized yet. Among solid organ transplant patients, B.
henselae infection is uncommon with different clinical
manifestations including disseminated diseases.27 Recently,
several reports describe cases of bartonellosis in transplant
recipients.28,29 To date, there are no available results about
B. henselae seroprevalence in patients awaiting transplant
who will undergo severe immunosuppressive therapy.
This study investigated the seroprevalence of B. hense-
lae in patients awaiting heart transplant in comparison toof Bartonella henselae in patients awaiting heart transplant in
15), http://dx.doi.org/10.1016/j.jmii.2015.05.001
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+ MODELhealthy controls, who were enrolled in the Regional
Reference Laboratory of Transplant Immunology of Second
University of Naples, Italy.
Patients and methods
In 2013, we collected serum samples from 38 patients
awaiting heart transplant and from 50 volunteers (control
group), enrolled at the Laboratory of Transplant Immu-
nology of Second University of Naples. Following blood
collection, serum was separated by centrifugation and
stored at 20C. The patients selected and enrolled on the
waiting list for heart transplantation have severe symptoms
of heart failure, angina, or intractable rhythm distur-
bances, and they are in severe clinical condition (ejection
fraction < 30% and maximal oxygen consumption < 8 mL/
kg/min) with no alternative form of treatment available.30
Once a patient with severe congestive heart failure has
been identified as having a limited life expectancy and
severely impaired quality of life, cardiac transplantation
should be considered.30 These patients in the pretransplant
period were not subjected to any immunosuppressive drug
therapy and had no previous infectious diseases.
Exclusion criteria for the control group were any clinical
history of lymphadenopathy and/or fever in the last 6
months. Patients and controls were normalized for cat
exposure. None of the individuals included in this study
presented clinical symptoms. Written informed consent was
obtained from patients and volunteers according to the
Declaration of Helsinki.
Serological testing
A commercially available Bartonella indirect immunofluo-
rescent assay (IFA; Focus Diagnostics, Cypress, CA, USA)
was used to assess the qualitative detection and semi-
quantitation of human serum IgM and IgG antibodies to B.
henselae and Bartonella quintana according to the manu-
facturer’s instructions. In the first stage, suitable dilutions
of patient sera were added to appropriate slide wells in
contact with the substrate for IgM and IgG, respectively. In
the second stage, fluorescein-labeled antibody to IgM or
IgG, was added, respectively. After the slide was washed,
dried, and mounted, it was examined by fluorescence mi-
croscopy (Zeiss, Wetzlar, Germany) at magnifications of
40 and 100. Each kit included positive and negativeTable 1 Seroprevalence of Bartonella henselae in patients w
controls
Variables Advanced heart fai
Age (y) 52.1  17.0
Comorbidity 1.41  0.96
Bartonella antibody (%) 21
Valve disease (%) 16.2
Previous myocardial infarction (%) 37.8
Diabetes (%) 18.9
Hypertension (%) 24.3
Renal failure (%) 47.1
Please cite this article in press as: Picascia A, et al., Seroprevalence
Southern Italy, Journal of Microbiology, Immunology and Infection (20controls. Positive reactions appeared as bright apple-green
fluorescent bacteria. According to the recommendations of
the manufacturer, titers from 1:20 for IgM and 1:64 for IgG
were considered positive.
Data analysis
Quantitative data were expressed as numbers and per-
centages. Categorical variables were analyzed using the
Chi-square test and continuous variables using one-way
analysis of variance (ANOVA). A p value < 0.05 was
considered significant.
Results
Serum samples of 38 patients awaiting heart transplant and
50 healthy donors were examined using IFA. In our study, a
B. henselae antibody significant positivity rate of 21%
(n Z 8) was found in patients awaiting heart transplant
(pZ 0.002; Table 1). Seroprevalence of Bartonella was not
significantly associated with age, sex, ischemic and non-
ischemic dilated cardiomyopathy, and other clinical pa-
rameters (p > 0.05, data not shown), whereas, the
differences in comorbidity between cases and controls
were statistically different (1.41  0.96 vs. 0.42  0.32;
p Z 0.001). Moreover, the age of patients on the waiting
list for heart transplant was higher than the control group
(52.1  17.0 vs. 38.8; p Z 0.001). The prevalence of
comorbidities evaluated (dilated cardiomyopathy, valve
disease, renal failure, diabetes, and hypertension) and the
differences between cases and controls are reported in
Table 1.
In Table 2, we report in detail the B. henselae seropos-
itivity of patients awaiting heart transplant (n Z 8) that
resulted positive to IgM or IgG antibodies. The highest
antibody dilution with a positive reaction was indicated. We
found a positive rate of 8% (n Z 3) with p > 0.05 for IgM,
whereas a significant value was found for IgG with 13%
(n Z 5) of positivity (p Z 0.02). In Table 2, demographic
and clinical characteristics of patients are also reported. All
controls resulted negative for both IgM and IgG antibodies
and they have shown only a low percentage of hypertension
and mitral prolapsed. Fig. 1 shows the representative IFA
images of one patient who tested positively to B. henselae
IgG (A), and a negative control of B. henselae IgG (B). No
individuals included in this study showed positive reactionsith advanced heart failure awaiting heart transplant and in
lure (n Z 38) Controls (n Z 50) p
38.0  8.0 0.001
0.42  0.32 0.001
0 0.002
2.0 0.016
0 0.001
0 0.001
8 0.005
0 0.000
of Bartonella henselae in patients awaiting heart transplant in
15), http://dx.doi.org/10.1016/j.jmii.2015.05.001
Table 2 Seropositivity of Bartonella henselae immunoglobulin (Ig)M and IgG antibodies in patients living in Campania Region
awaiting heart transplant
Sex
(M/F)
Age
(y)
IgM anti-B.
henselae
IgG anti-B.
henselae a
Heart disease Valve
implantation
Diabetes Hypercholesterolemia Hypertension Transfusion
F 8 // 1:128 Nonischemic DCM Yes No No No Yes
M 64 1:20 // Ischemic DCM No Yes Yes Yes No
M 50 // 1:128 Ischemic DCM No No Yes Yes No
M 67 // 1:64 Ischemic DCM No No Yes No Yes
M 55 // 1:64 Nonischemic DCM Yes No No No No
F 56 1:20b // Nonischemic DCM No No No No No
M 33 1:20 // Ischemic DCM No No Yes No Yes
M 66 // 1:64 Ischemic DCM No No Yes Yes No
a The positivity rate of IgG anti-Bartonella is statistically significant with p < 0.05 (p Z 0.02).
b Different sampling times have revealed seroconversion in live patients of IgM in IgG with 1:64 titer.
DCM Z dilated cardiomyopathy; F Z female; M Z male.
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+ MODELto B. quintana antibody. All patients found to be positive
for IgG and IgM antibodies were monitored at least twice at
different sampling times, confirming the result or the
seroconversion in live patients of IgM in IgG with 1:64 titer.Discussion
In the present study, we report Bartonella serological sta-
tus of a small group of patients awaiting heart transplant.
We established that the overall prevalence of B. henselae
seropositivity was of 21% (nZ 8) in patients awaiting heart
transplant (p Z 0.002). In particular, we found that 8% of
patients were positive for IgM (p Z 0.14) and 13% were
positive for IgG antibodies (p Z 0.02). To our knowledge,
this is the first report on the seroprevalence of B. henselae
on patients awaiting heart transplant in our region and in
Italy. Our analysis supports the hypothesis that age is aFigure 1. Immunofluorescent assay images. (A) Serum sample
henselae immunoglobulin G, magnification 100. (B) Negative con
facturer (Focus Diagnostics, Cypress, CA, USA), magnification 40.
Please cite this article in press as: Picascia A, et al., Seroprevalence
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infection in the patient population. Indeed, patients are
older than controls and are likely to have had more years of
possible exposure to infective agents. However, in our
population, this factor together with the state of general
impairment of these patients due to their severe heart
failure is likely to increase the prevalence/incidence of
infection. Heart transplant is the only therapeutic option
for the survival of patients with severe end-stage heart
failure.29,30 Post-transplant, under the influence of immu-
nosuppressive therapy, these patients are at risk for
developing infectious diseases.31,32 Despite significant ad-
vances in the management of solid organ transplant, in-
fections still remain a considerable factor influencing
transplant outcome.32
Although, in the post-transplant period, many risk fac-
tors for infection are known, the epidemiology of infections
in patients awaiting heart transplant and the effect ofof a patient awaiting heart transplant positive to Bartonella
trol of B. henselae immunoglobulin G supplied by the manu-
of Bartonella henselae in patients awaiting heart transplant in
15), http://dx.doi.org/10.1016/j.jmii.2015.05.001
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remain to be investigated.33 Most of the guidelines for
pretransplant management recommend the screening of
patients potentially exposed to infectious agents, however,
they do not include fastidious pathogens such as B.
henselae.34
Bartonella infections display different progression and
organ involvement due to a balance between host and
bacterial factors.12 Recently, several reports described
cases of solid organ transplant recipients who developed
disseminated infections with B. henselae depending on the
immunosuppressive therapy, at several times from trans-
plant.27,28,35 Usually, the transmission of B. henselae occurs
via traumatic contact with infected cats or cat fleas.13
Some studies support the possibility of Bartonella in-
fections through blood transfusion, probably due to its
intraerythrocytic viability during storage at 4C.36 In addi-
tion, in patients who develop bartonellosis within a few
months after transplant, a possible source of transmission
of B. henselae could be the organ donor.37 Indeed, Scolfaro
et al37 reported a case of liver bartonellosis in a recipient
whose donor was positive for B. henselae IgG antibodies.
Moreover, in immunocompromised patients a possible
source of bartonellosis could be the reactivation of previous
infections, although this complication is uncommon for
bacteria.27 In this regard, Bartonella spp., as intracellular
bacteria, may develop various processes to facilitate their
uptake into the intracellular compartment of the host
cells.1 Intraerythrocytic colonization is a hallmark of B.
henselae also, if endothelial cells have been assumed as a
potential niche in Bartonella infections, in vivo.2,3 How-
ever, an increasing number of studies have demonstrated
that an alternative niche may be represented by HSCs4 and
EPCs.5,37e40 Mobilized EPCs could carry this pathogen to
other organs and, more important, to the endothelium of
microcirculation.5 Moreover, B. henselae induces endothe-
lial proliferation through apoptosis inhibition thus allowing
its permanence into cell host habitat.6,7 B. henselae colo-
nized cells might play a central role not only in the path-
ogenesis of infection but also in the possible reactivation;
this issue remains to be elucidated.41 Therefore, during the
pretransplant period B. henselae infection could evolve in
several complications such as endocarditis.15,42 However,
post-transplant, as a consequence of immunosuppressive
therapy, bacterial reactivation could result in a severe and
disseminate bartonellosis that could compromise several
organs.
Therefore, an early diagnosis and an adequate treat-
ment could be crucial in the pretransplant period in order
to prevent the course of the disease in the post-transplant
phase when the patients are immunocompromised.27
However, a substantial portion of the pretransplant pa-
tients had acute infection and a positive IgM serology.
In conclusion, our retrospective observational study,
although performed on a small number of pretransplant
patients at a Regional Hospital not allowing generalizability
of the results suggests that B. henselae, together with
other emerging bacteria, should be included as a routine
analysis in the list of opportunistic infections. Therefore,
the pretransplant monitoring of Bartonella infections may
be useful in the management of patients in post-transplant
phase.Please cite this article in press as: Picascia A, et al., Seroprevalence
Southern Italy, Journal of Microbiology, Immunology and Infection (20Conflicts of interest
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